Pediatric neurosurgery

Rady Children's Appoints Vijay A. Patel, MD, as Director of Pediatric Complex Sinus and Skull Base Surgery Program and Professor of Otolaryngology at UC San Diego

Retrieved on: 
Martedì, Maggio 7, 2024
University, Rady Children's Hospital, Hospital, Pediatric neurosurgery, Crystal skull, Doctor of Philosophy, Pathology, Patient, Physician, Child, Neurosurgery, SAN, Division, Head, UC, Nursing

SAN DIEGO, May 7, 2024 /PRNewswire/ -- Rady Children's Hospital-San Diego , one of the nation's top 10 pediatric health care systems, and the University of California San Diego are pleased to announce that Vijay A. Patel, MD, has been appointed as Director of the Pediatric Complex Sinus and Skull Base Surgery Program at Rady Children's Hospital and assistant professor of otolaryngology at UC San Diego School of Medicine.

Key Points: 
  • SAN DIEGO, May 7, 2024 /PRNewswire/ -- Rady Children's Hospital-San Diego , one of the nation's top 10 pediatric health care systems, and the University of California San Diego are pleased to announce that Vijay A. Patel, MD, has been appointed as Director of the Pediatric Complex Sinus and Skull Base Surgery Program at Rady Children's Hospital and assistant professor of otolaryngology at UC San Diego School of Medicine.
  • Dr. Patel will lead a multidisciplinary team of physicians committed to providing comprehensive care for pediatric patients with complex sinonasal and skull base lesions.
  • At Rady Children's, the Pediatric Complex Sinus and Skull Base Surgery Program offers an endoscopic endonasal approach that removes or alleviates the source of the problem while minimizing damage to surrounding critical structures.
  • "Rady Children's Hospital-San Diego and UC San Diego have long set the standard for pediatric health care on the West Coast and beyond," said Dr. Patel.

Rady Children's Appoints Praveen Raju, MD, PhD, as the Nathan Gordon Chair and Medical Director of Neuro-Oncology Program

Retrieved on: 
Martedì, Aprile 2, 2024
Research, Diagnosis, Boston Children's Hospital, Brain, Health, Growth, Neurology, MSTP, Memory, Genetics, SAN, Patient, UC, Cancer, Medulloblastoma, Child, University, Neurosurgery, Doctor of Philosophy, Neuro, MD, Molecular biology, NIH, Laboratory, Pediatric neurosurgery, Neoplasm, Infant, Nathan Gordon, Hospital, Spinal cord, Pediatrics, Neuro-Oncology (journal), Medical director, Genetic distance, Nursing

At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.

Key Points: 
  • At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.
  • As part of Rady Children's nationally recognized care team, Dr. Raju will spearhead the growth of the Neuro-Oncology Program and advance research efforts on pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise, Dr. Raju aims to address different forms of pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise into the Neuro-Oncology Program, Dr. Raju aims to address the different forms and distinct molecular subtypes of pediatric brain and spinal tumors.

Dr. Ben Carson & Dr. Michael Beckwith Pray for the Nation on Super Tuesday, Hosted by Soaak Technologies

Retrieved on: 
Mercoledì, Marzo 6, 2024
Theta, Nation, Love, Freedom, EMDR, Housing, Hope, Death, Super, Health, Safety, Thermography, Brain mapping, Pediatric neurosurgery, God the Father, Agape International Spiritual Center, Metabolic typing, Pan American Health Organization, Patient, Neurosurgery, Low-level laser therapy, Former, Consciousness, Johns Hopkins Hospital, Beauty, Medical device

TULSA, Okla., March 6, 2024 /PRNewswire/ -- Soaak Technologies, Inc. (https://www.soaak.com/), a health-tech company known for their clinically proven sound frequency composition therapies, welcomed Dr. Ben Carson and Dr. Michael Beckwith for Super Tuesday 2024 to visit the new state of the art Soaak Clinic located in Tulsa Oklahoma, noting the importance of advancements in technology in health and wellness being a matter that should have extreme attention on both sides of the political aisle heading into the 2024 elections. Dr. Ben Carson being the Chief of Pediatric Neurosurgery at Johns Hopkins Hospital, Former United States Secretary of Housing and Urban Development, and Former Presidential Candidate (2016), and Dr. Michael Beckwith, author, and founder and spiritual director of the Agape International Spiritual Center, along with Soaak Executives, led a prayer focused on healing and uniting the nation. The visit comes on the heels of the U.S. Air Force Awarding Soaak Technologies a second contract to Enhance Airmen's Performance, using their proprietary Sound Frequency Compositions.

Key Points: 
  • "We are honored that Dr. Ben Carson and Dr. Michael Beckwith joined us at our Soaak Clinic to bear witness to how we are affecting change on such a notable day for America.
  • To kickstart the Super Tuesday event, Soaak Executive Chairman Henry Penix, alongside Dr. Ben Carson and Dr. Michael Beckwith, led a prayer for the Nation.
  • Dr. Ben Carson began the prayer by saying, "Heavenly Father, we gather here in gratitude for the peace, safety, and freedom we enjoy.
  • "I was honored to meet Dr. Carson for the first time and join him in prayer for our Nation on this Super Tuesday," stated Dr. Michael Beckwith.

Rhaeos, Inc. Strengthens Leadership Team with Appointment of Dr. David Limbrick as Chief Medical Officer

Retrieved on: 
Martedì, Novembre 28, 2023
CNS, Principal, Research, Chicago Innovation Awards, Neuroimaging, Northwestern University, Neurosurgical anesthesia, Public service, Accreditation, Chiari malformation, Humanism, Patient, Accreditation Council, Virginia Commonwealth University, Congress of Neurological Surgeons, FDA, Neuro, Hydrocephalus, CMO, Doctor of Philosophy, Congress, Skin, Quality of life, Pediatric neurosurgery, Veterinary medicine, Medical device, Medicine, MD, Chiari, Neurosurgery

EVANSTON, Ill., Nov. 28, 2023 /PRNewswire/ -- Rhaeos, Inc., a clinical-stage medical device technology company dedicated to advancing diagnostic solutions for hydrocephalus patients, proudly welcomes David D. Limbrick, Jr., MD, PhD, as its new Chief Medical Officer (CMO).

Key Points: 
  • EVANSTON, Ill., Nov. 28, 2023 /PRNewswire/ -- Rhaeos, Inc., a clinical-stage medical device technology company dedicated to advancing diagnostic solutions for hydrocephalus patients, proudly welcomes David D. Limbrick, Jr., MD, PhD, as its new Chief Medical Officer (CMO).
  • Dr. Limbrick is currently a Professor at Virginia Commonwealth University, where he joined as the Chair of the Department of Neurosurgery in 2023.
  • "I am very excited to join the Rhaeos team after collaborating closely with them for the past two years," stated Dr. Limbrick.
  • The company looks forward to the continued advancement of their mission to have a global impact on neurosurgery and hydrocephalus management.

LA Kings Renew Long-standing Partnership With Children’s Hospital Los Angeles and Announce a New Commitment of $1 Million

Retrieved on: 
Giovedì, Ottobre 26, 2023
Hockey, Marketing, Communications, Philanthropy, Hospitals, Teens, Sports, Parenting, Children, Baby, Maternity, Fund Raising, Foundation, Family, Other Philanthropy, Consumer, Health, Crypto.com, U.S. Army Community Relations, Vancouver Canucks, Children's Hospital Los Angeles, Sport, Heart, Neurosurgery, Hope, Chicken à la King, Organization, Pediatric neurosurgery, Crypto.com Arena, Research, Hall, Senior, Division, Partnership, CHLA, Blood, 1985–86 Vancouver Canucks season, Community, NHL, Cancer, Collection, 1993–94 Florida Panthers season, Patient, Florida Panthers, Nursing, Video game, Hospital, Los Angeles Kings

The partnership between the LA Kings and CHLA has proven to be a powerful force in raising awareness and support for the young patients served by the hospital.

Key Points: 
  • The partnership between the LA Kings and CHLA has proven to be a powerful force in raising awareness and support for the young patients served by the hospital.
  • To date, the LA Kings and the award-winning charitable arm of the team, the Kings Care Foundation, have donated over $2 million to support research at CHLA.
  • “For many years, we have had the privilege of working closely with Children’s Hospital Los Angeles,” says Jennifer Pope, Senior Vice President, Community Relations and Hockey Development, LA Kings.
  • As the official children’s hospital of the LA Kings, Children’s Hospital Los Angeles will continue to have a significant brand presence across the team and at Crypto.com Arena on game days.

Enrollment Completed for HOPE PMR Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable MR Imaging® System

Retrieved on: 
Mercoledì, Agosto 9, 2023
Medical Devices, Health, Neurology, Health Technology, Research, Science, Radiation, PMR, HOPE, Portable, Multimedia, Index, MRI, Hydrocephalus, Data analysis, Patient, Neurosurgery, Hospital, Pediatric neurosurgery, FDA, Nationwide, Medical imaging, Nursing, Hyperfine structure

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced completed enrollment for the multi-site observational study, HOPE PMR (Portable MRI for Children with Neurological Injury—A Pilot Study using Hydrocephalus as an Index Condition).

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced completed enrollment for the multi-site observational study, HOPE PMR (Portable MRI for Children with Neurological Injury—A Pilot Study using Hydrocephalus as an Index Condition).
  • The study used pediatric hydrocephalus as an index condition to assess if Swoop® system images can be used to accurately detect shunt malfunctions and assess ventricular size.
  • "The Swoop® system represents a promising shift in brain imaging.
  • Our collaboration with Hyperfine, Inc. paves the way for improvements in brain imaging, benefiting this vulnerable patient population."

Anuncia Medical Successfully Launches Second Generation Device to Treat Hydrocephalus at Several Leading Neurosurgical Centers Across the United States

Retrieved on: 
Mercoledì, Luglio 26, 2023
Nationwide Children's Hospital, CPC, OH, Quality of life, Medical school, Global health, Brain, Neurosurgery, Today, Scalp, Endoscopic third ventriculostomy, Organization, Therapy, Literature, Hydrocephalus, Soldering, Journal, Medical University of South Carolina, Patient, Risk, Data, CSF, Neurological disorder, ETV, Pediatric neurosurgery, FDA, Hospital, COVID-19, Pharmaceutical industry, Medical device, African

SCOTTSDALE, Ariz., July 26, 2023 /PRNewswire/ -- Anuncia Medical Inc. ("Anuncia" or the "Company"), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce the successful U.S. commercial launch of the ReFlow™ Mini Flusher device. Neurosurgeons in the US and soon internationally will now have a new option to reduce the impact of hydrocephalus by providing better access to potentially life-saving therapy for the 30 million patients worldwide suffering from this neurological disorder. Hydrocephalus is a chronic neurological condition in which excess CSF accumulates in the brain, often causing severe symptoms, frequent hospitalizations, and ongoing health concerns, and may be fatal if left untreated.

Key Points: 
  • The just launched second-generation ReFlow Mini Flusher is FDA-cleared for use in patients living with hydrocephalus or similar conditions.
  • Its reduced size and profile  are designed to better support a broader hydrocephalus patient population, from infants to older adults.
  • Since the ReFlow Mini became available earlier this month, multiple leading centers across the country have successfully implanted the technology.
  • We share a common mission with leading neurosurgical and hydrocephalus organizations of improving access to better care and quality of life and providing peace of mind to patients.

Anuncia Medical Inc. Announces Published Data with Promising Clinical Outcomes Using the ReFlow™ Ventricular System In-Line with Hydrocephalus Shunts

Retrieved on: 
Martedì, Maggio 23, 2023
Maintenance, Medical University of South Carolina, Intraparenchymal hemorrhage, Food and Drug Administration, Medical school, Brain, Scalp, Hydrocephalus, Soldering, Hospital, Patient, Child, Surgeon, CSF, Neurosurgery, Pediatric neurosurgery, Health, FDA, ICP, Family, Intracranial pressure, Food, Medical device, Pharmaceutical industry

SCOTTSDALE, Ariz., May 23, 2023 /PRNewswire/ -- Anuncia Medical Inc. ("Anuncia" or the "Company"), a company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce that an article highlighting its FDA cleared and CE Marked ReFlow™ Ventricular System "Gen 1" with Hydrocephalus shunts in patients suffering from chronic shunt occlusions, has been published in Pediatric Neurosurgery. Two years prior to being implanted with the ReFlow™ System, 7 of the 9 patients represented in the publication experienced a combined total of 14 proximal shunt failures that required revision. In the 2-4 years following ReFlow™ implantation and use to maintain flow, only 1 proximal shunt failure occurred amongst the 9 patients. As revisions are typically associated with expensive hospital admissions for both the child and family, reducing the number of revisions needed is invaluable to those impacted. 

Key Points: 
  • Yearly, tens of thousands of adults and children with hydrocephalus undergo revision surgeries at U.S. hospitals to replace occluded shunts.
  • "The failure rate of shunts after implantation is unacceptably high, with most failures happening from occlusion/clogging of the ventricular catheter.
  • With >4 years of clinical follow-up and feedback from the ReFlow "Gen 1" device, Anuncia Medical has developed a smaller, easier-to-use ReFlow System Mini "Gen 2" device.
  • "The ReFlow 'Gen 1' and the smaller ReFlow System Mini, represent almost a decade of work with hydrocephalus clinical experts and talented engineers," shared Elsa Chi Abruzzo, President & CEO of Anuncia Medical.

Asensus Surgical Announces Ludwig Maximilians University in Germany to Initiate Senhance Pediatric Surgery Program

Retrieved on: 
Martedì, Novembre 8, 2022
GLOBE, Tremor, Filtration, Ludwig Maximilian University of Munich, Burns, NYSE, Accident, Elective surgery, Intelligence, Research, Health, Sale, Abdominal wall, Pediatric neurosurgery, Pectus excavatum, Thorax, Pediatric urology, Company, RESEARCH, PARK, Deep learning, Birth, Patient, Growth, CEO, Surgeon, Medical device, Dentistry, Medicine

We are very excited that the LMU University Hospital will be utilizing a Senhance System as part of their pediatric surgery department.

Key Points: 
  • We are very excited that the LMU University Hospital will be utilizing a Senhance System as part of their pediatric surgery department.
  • This is a significant milestone for Asensus as this represents the first Senhance program devoted entirely to pediatric procedures, said Anthony Fernando, Asensus Surgical President and CEO.
  • We look forward to partnering with the pediatric team at LMU University Hospital to transform the way they deliver care to their pediatric patients.
  • The platform will be a great asset to our hospital, and we are very excited to launch our Senhance pediatric surgical program.

Anuncia Medical, Inc., clearance for the ReFlow® System Mini for the treatment of patients with hydrocephalus

Retrieved on: 
Venerdì, Settembre 30, 2022
Adult, Medical University of South Carolina, Nursing care plan, Hydrocephalus, Neurosurgery, CSF, MD, FDA, Food, Pediatric neurosurgery, News, Soldering, Patient, MS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CEO, Solution, Diagnosis, Caregiver, Healthcare Facilities Accreditation Program, Scalp, Medical school, Cerebrospinal fluid, Pharmaceutical industry, Medical device

Anuncia Medical announced FDA clearance of ReFlow System Mini for the treatment of cerebrospinal fluid (CSF) disorders.

Key Points: 
  • Anuncia Medical announced FDA clearance of ReFlow System Mini for the treatment of cerebrospinal fluid (CSF) disorders.
  • The FDA 510(k) clearance allows Anuncia Medical to commercialize the ReFlow System Mini in the US.
  • "This is very exciting news for Anuncia and for the hydrocephalus community," said Elsa Chi Abruzzo, President & CEO of Anuncia.
  • The ReFlow System Mini has a ReFlow Mini Flusher and ReFlow Ventricular Catheter.